Greenland Mines Ltd (GRML)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Greenland Mines Ltd Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Markus Wiklund Brummer Multi-Strategy AB | 370,049 | $106,944.31 | $122,116.17 | $15,171.86 | 14.19% |
Greenland Mines Ltd (GRML) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Greenland Mines Ltd ever had a stock split?
Greenland Mines Ltd Profile
| Metals & Mining Industry | Materials Sector | Joseph A. Sinkule CEO | NASDAQ (NMS) Exchange | 49876K103 CUSIP |
| US Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Greenland Mines Ltd. is a prominent biotechnology firm dedicated to pioneering innovative therapies aimed at addressing neurodegenerative diseases. Since its inception on August 2, 2004, by founder Joseph Sinkule, the company has been headquartered in Omaha, NE. With a focus on research and development, Greenland Mines Ltd. is committed to enhancing the quality of life for patients suffering from these debilitating illnesses by offering cutting-edge solutions.
Products and Services
- Cell Therapy
Greenland Mines Ltd. specializes in cell therapy, a groundbreaking approach that involves the administration of living cells to replace or repair damaged tissues or cells. This therapy aims to rejuvenate and restore functionality in afflicted areas of the nervous system, ultimately improving patient outcomes.
- Gene Therapy
The company offers gene therapy, which involves the modification of genes to treat or prevent diseases. This innovative technique includes inserting healthy genes into a patient's cells to correct genetic defects that can lead to neurodegenerative conditions. By focusing on the root cause, gene therapy has the potential to provide long-lasting relief and recovery from these diseases.
